Overview

Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated in non-surgical cancer patients will be investigated.
Phase:
Phase 3
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
Dalteparin
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight